Trial Profile
A Phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Trabedersen (Primary) ; Dexamethasone
- Indications COVID 2019 infections; Pneumonia; Respiratory insufficiency
- Focus Therapeutic Use
- Sponsors Oncotelic Therapeutics
- 13 Mar 2023 Status changed to completed, according to an Oncotelic Therapeutics media release.
- 13 Mar 2023 According to an Oncotelic Therapeutics media release, this trial was completed in South America.
- 12 Oct 2022 According to a Oncotelic Therapeutics media release, Oncotelic awarded BARDA funding for development of OT-101 for long COVID